All In Biotech

Drug Trial Radar · NCT07617194

Study of AHB-171 in Chronic Hepatitis B Participants

A Phase 1 Study in Chronic Hepatitis B Participants to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-171

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Oct 8, 2027

Study completion Aug 14, 2028

Sponsor

Lead sponsor
AusperBio Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.

Conditions

  • Hepatitis B, Chronic

Interventions

  • AHB-171Drug

    Injection

  • Placebo matching [Investigational Product]Drug

    Injection

  • Nucleos(t)ide Analogue (NA)Drug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) [Safety and Tolerability]Time frame: Up to 72 weeks
  2. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the maximum observed plasma concentration (Cmax) of AHB-171.Time frame: Up to 72 weeks
  3. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the area under the concentration-time curve extrapolated to infinity (AUCinf ) of AHB-171Time frame: Up to 72 weeks
  4. Incidence of clinically significant changes in Vital Signs [Safety and Tolerability]Time frame: Up to 72 weeks
  5. Incidence of clinically significant changes in cardiac parameters [Safety and Tolerability]Time frame: Up to 72 weeks
  6. Incidence of laboratory abnormalities [Safety and Tolerability]Time frame: Up to 72 weeks
  7. The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: area under the curve from the time of dosing to the last measurable concentration (AUClast) of AHB-171Time frame: Up to 72 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • New Zealand Clinical Research

    Grafton, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.